Autres langues Matricelf Ltd

Actions

MTLF

IL0011767915

Recherche biotechnologique et médicale

Marché Fermé - TEL AVIV STOCK EXCHANGE 16:24:11 05/10/2026			Varia. 5j.	Varia. 1 janv.
245,80 ^ILa	-3,61%		-4,02%	-55,38%

03/09	Matricelf reçoit un avis favorable de la FDA sur les éléments clés de son futur premier essai clinique humain pour le programme NewRal contre les lésions de la moelle épinière	CI
27/08	Matricelf Ltd publie ses résultats pour le semestre clos le 30 juin 2026	CI

Autres langues

03/09	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program
03/09	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program
27/08	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026
09/07	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study
09/07	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones
23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury
22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury
17/06	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant
30/03	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation
24/03	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025
24/03	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury
24/03	Matricelf Ltd Auditor Raises 'Going Concern' Doubt
04/03	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant
03/03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
03/03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
27/02	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
26/02	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation
21/08/25	Tel Aviv University: Israeli Breakthrough: First Human Trial of Engineered Spinal Cord
03/08/25	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025
12/03/25	Cellino and Matricelf, New Hope for Spinal Cord Injuries
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments